VERAXA Biotech AG (NASDAQ: VRXA) has announced that its VXA-222 bispecific antibody-drug conjugate (bsADC) program has advanced beyond the discovery phase into the next stage of development, following the completion of the discovery portion of its collaboration with OmniAb Inc. The collaboration, which began in May 2025 (https://nnw.fm/nIprz), has delivered a portfolio of therapeutic antibody binders. VERAXA is now responsible for engineering the final bispecific ADC candidate and advancing preclinical validation.
Although VXA-222 is not based on VERAXA's BiTAC platform, it leverages the company's proprietary antibody engineering, linker and conjugation technologies, making it one of the company's more advanced development programs. The progression of VXA-222 underscores VERAXA's commitment to building a diversified oncology pipeline that includes bispecific antibody-drug conjugates, T-cell engagers, and engineered antibody formats targeting difficult-to-treat cancers.
In parallel with the program milestone, VERAXA has expanded its intellectual property portfolio with its first BiTAC-related patent filings, along with additional patents supporting conjugation chemistry, payloads, and antibody technologies. The company now holds more than 50 granted owned or exclusively licensed patents across 26 patent families in 14 countries. Newly filed applications are expected to extend protection into at least 2047, providing a robust foundation for its next-generation antibody-based therapies.
The expansion of the patent portfolio is a strategic move to protect VERAXA's innovative approaches in antibody-drug conjugates and bispecific T-cell engagers. By securing intellectual property rights, the company aims to maintain a competitive edge in the rapidly evolving field of cancer immunotherapy. This is particularly important as the market for antibody-drug conjugates is projected to grow significantly, driven by the success of these therapies in various solid and hematological malignancies.
VERAXA's progress with VXA-222 and its strengthened IP position come at a time when the oncology landscape is shifting toward more targeted and potent therapies. Bispecific ADCs are designed to selectively deliver cytotoxic drugs to tumor cells while sparing healthy tissues, potentially improving efficacy and reducing side effects compared to traditional chemotherapy. The company's focus on next-generation antibody technologies positions it well to capitalize on these trends.
Investors and industry observers will be watching closely as VERAXA moves VXA-222 through preclinical validation and toward clinical trials. The successful advancement of this program could validate the company's proprietary technologies and pave the way for future collaborations or partnerships. Moreover, the expanded patent portfolio provides a layer of security that may attract potential licensors or investors.
VERAXA continues to demonstrate its ability to execute on its development milestones while simultaneously building a strong intellectual property estate. With a pipeline that spans multiple therapeutic modalities, the company is well-positioned to address some of the most challenging cancers. As the VXA-222 program progresses, further updates on preclinical data and development timelines will be critical to assess its potential impact on the oncology market.
